Towards Healthcare
Age-related Macular Degeneration (AMD) Drugs Market to Rise USD 29.04 Bn by 2034

Age-related Macular Degeneration (AMD) Drugs Market 2025 North America Leads with 41% Share

According to forecasts, the global age-related macular degeneration (AMD) drugs market will grow from USD 10.57 billion in 2024 to USD 29.04 billion by 2034, with an expected CAGR of 10.66%. Rising patient demand for a better quality of life is estimated to drive the growth of the market over the forecast period. The U.S. hub for clinical trials exploring next-generation AMD drugs, including gene therapies, stem-cell therapies, and long-acting anti-VEGF agents, reinforces the North America region’s leadership.

Content

  • Insight Code: 6047
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: August 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Shivani Zoting is a dedicated research analyst specializing in the healthcare industry. With a strong academic foundation, a B.Sc. in Biotechnology and an MBA in Pharmabiotechnology, she brings a unique blend of scientific understanding and market strategy to her research.

Shivani contributes to Towards Healthcare and plays an active role at Precedence Research, where she focuses on delivering in-depth market intelligence, competitive analysis, and trend forecasting across pharmaceuticals, medical devices, digital health, and healthcare services. Her insights support healthcare companies, investors, and policymakers in making data-backed decisions in a highly regulated and rapidly evolving sector.

Additionally, Shivani collaborates with Statifacts, further expanding her healthcare domain reach by engaging in diverse projects across global markets. Her strength lies in transforming complex clinical and commercial data into strategic narratives that help stakeholders navigate the future of healthcare.

Talk to us
FAQ's

The age-related macular degeneration (AMD) drugs market is valued at USD 11.69 billion in 2025 and is on track to reach USD 29.04 billion by 2034, witnessing a steady CAGR of 10.66% during the forecast span.

North America is leading the age-related macular degeneration (AMD) drugs market share 41% due to the rapid adoption of novel therapies, strong presence of key market players, rising awareness, and early diagnosis.

The age-related macular degeneration (AMD) drugs market includes six segments including by disease type, by drug class, by route of administration, by distribution channel, by end-user, and by region.

Key trends include the strategic collaborations and partnerships, government initiatives & funding, and rising healthcare expenditure.

he American Macular Degeneration Foundation (AMDF), Government of Canada, Patient and Professional Organizations, U.S. Food and Drug Administration, clinicaltrials.gov, Macular Society Beating Macular Disease, AMD Alliance International Member Organizations, and GOV.UK, among others.
Any Questions